Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.
Factor VIII (FVIII) is an important cofactor in blood coagulation cascade. It is a multidomain protein that consists of six domains, NH2-A1-A2-B-A3-C1-C2-COOH. The deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. Replacement therapy using recombinant FVIII (rFVIII) is the first line of therapy, but a major clinical complication is the development of inhibitory antibodies that abrogate the pharmacological activity of the administered protein. FVIII binds to anionic phospholipids (PL), such as phosphatidylinositol (PI), via lipid binding region within the C2 domain of FVIII. This lipid binding site not only consists of immunodominant epitopes but is also involved in von Willebrand factor binding that protects FVIII from degradation in vivo. Thus, we hypothesize that FVIII-PL complex will influence immunogenicity and catabolism of FVIII. The biophysical studies showed that PI binding did not alter conformation of the protein but improved intrinsic stability as measured by thermal denaturation studies. ELISA studies confirmed the involvement of the C2 domain in binding to PI containing lipid particles. PI binding prolonged the in vivo circulation time and reduced catabolism of FVIII in hemophilia A mice. FVIII-PI complex reduced inhibitor development in hemophilia A mice following intravenous and subcutaneous administration. The data suggest that PI binding reduces catabolism and immunogenicity of FVIII and has potential to be a useful therapeutic approach for hemophilia A.
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, 526 Hochstetter Hall, Amherst, New York 14260, USA.
Aaron
A
Peng
Robert M
RM
Straubinger
Sathy V
SV
Balu-Iyer
D000818:Animals; D005169:Factor VIII / Q000378:metabolism*; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D008055:Lipids / Q000737:chemistry*; D008297:Male; D051379:Mice; D010716:Phosphatidylinositols / Q000032:analysis*
D008055:Lipids; D010716:Phosphatidylinositols; D005169:Factor VIII